Brigham Young University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Brigham Young University sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 7 completed early-phase tilt top decile by trial count

Brigham Young University: 10 sponsored US clinical trials, 1 recruiting.

Brigham Young University sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Older Adult, with 1 trials.

Top-decile sponsor footprint

Brigham Young University ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

What is open in the Brigham Young University pipeline

1 recruiting of 10 indexed (10% open); 7 completed (70%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Older Adult (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Brigham Young University: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Brigham Young University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Brigham Young UniversityAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Brigham Young University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Brigham Young University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this Brigham Young University page

10 registered trials is a research-attention snapshot, not an endorsement of Brigham Young University or any single study.

  • 1 of Brigham Young University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Older Adult is the condition Brigham Young University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Older Adult trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Brigham Young University pipeline card: 10 registered trials from official public datasets.Report a data error.